恆指升幅曾擴至逾300點 聯通及藥明生物漲8%及11% 申洲破頂
市場對國會與白宮於大選前就新一輪支援經濟方案達協議憧憬轉趨樂觀。美股期貨全面續彈不足0.5%。亞太區股市普遍向好，但除菲股升1.9%報6,231連續第三天急漲外，餘下升幅均少於0.8%。
本港截至8月止三個月失業率環比升0.3個百分點至6.4%逼近16年高，顯高於市場預期微升至6.2%。不過，恆指連升第四天，繼昨天反覆續升0.1%後，今早高開126點或0.5%報24,695，在科技股帶動，升幅曾擴至333點或近1.4%，高見24,903遇壓，現造24,754，續升185點或0.7%，成交額474億元。
逾半藍籌股造好，今天放榜的聯通(00762.HK)承昨天扭三連跌重越10天線勢，今早股價進一步升破牛熊線(5.75元)，最高見5.91元，現造5.84元，續漲8.1%。中移動(00941.HK)首三季純利按年微降0.3%至816億人民幣。花旗績後維持中移動「買入」評級及目標價76元不變，以反映股息預期和利潤可見度將對股價構成提振，並料來自移動服務收入可能於末季繼續回升。該股今早突破20天及10天線，最高見51.4元，現造51元，續彈2.1%。
小米-W(01810.HK)高見23.1元，現造22.75元，升2.5%。騰訊(00700.HK)四連漲，今早股價高見573元，暫受制上周三所創上市高位574元，曾倒跌低見563元，現造565.5元，續升0.2%。
阿里巴巴-SW(09988.HK)四連漲，股價穩步屢創上市新高，今早高見303.8元，現造301元，續升0.5%。傳阿里旗下螞蟻集團擬下周二開始招股，11月6日AH股同步上市。
藥明生物(02269.HK)今早股價突破上周一所創上市高位218元，最高見233元，現造224元，急漲11%，成交增至790萬股。內地臨床階段細胞治療平台公司藥明巨諾(JW Therapeutics)日前已開始IPO預演，據報集資額達3-3.5億美元(高於原先規模2.3億美元)。藥明巨諾由藥明生物母企藥明康德(02359.HK)與美國朱諾治療(Juno Therapeutics)共同創建。
金融股以建行(00939.HK)、工行(01398.HK)及港交所(00388.HK)表現最好，股價回升逾1%，分別高見5.68元/4.61元/373元。匯控(00005.HK)曾回升1.8%高見31.35元，現造30.9元，升0.3%。
申洲(02313.HK)先後獲花旗及大摩上調目標價至160元，該股今早突破上周四所創上市高位140.4元，最高見142.1元，現造141.7元，續升2.8%。
不過，舜宇(02382.HK)延續過去三連漲勢，今早進一步升至132.6元遇阻，掉頭倒跌1.8%報128.8元；瑞聲(02018.HK)高開報44.9元欠承接，掉頭續跌1.9%報43.85元。此外，公用及地產股也全面反覆受壓。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
